Artificial Intelligence in Indonesian Healthcare

By Sumona Bose

February 14, 2024

AI’s Rising Influence in Global Healthcare

Artificial intelligence (AI) is making waves in the healthcare industry worldwide. OpenAI’s ChatGPT, an AI language model, astounded the medical community by acing the United States Medical Licensing Exam without specialised training. Google’s Med-PaLM 2 mirrored this success, demonstrating AI’s potential to absorb and apply vast medical knowledge. AI’s  power also extends to research, with McMaster University and MIT using it to discover new antibacterial molecules, marking a significant step in the fight against antimicrobial resistance. The East Asian and Pacific region has also seen greater increase in AI employability in healthcare market.

Asia Pacific Healthcare AI Market Growth Outlook 2021-2027
Figure 1: Asia Pacific’s AI Market Report.

AI and Healthcare in Indonesia: Opportunities and Challenges

Indonesia, with its low physician-to-population ratio, stands to benefit immensely from AI’s potential. AI-powered chatbots, integrated with data from various sources, could enhance healthcare accessibility across the archipelago. The integration of AI with digital health platforms like Halodoc could potentially improve the quality of healthcare services in Indonesia. However, the journey towards AI integration is not without challenges. Bias in AI models, primarily trained on medical literature from high-income countries, is a significant concern. Indonesia must consider this bias when integrating AI with existing digital healthcare services. The use of local data, such as from Halodoc, is crucial for effective AI deployment in Indonesian healthcare.

Addressing Privacy Concerns and the Need for Regulation

Data acquisition for AI model training also raises serious privacy concerns. Despite the enactment of the Personal Data Protection Law in 2022, public unease over sensitive data leaks remains high in Indonesia. The country can learn from South Korea’s model of a centralised, secure, and ethical data-sharing system to build its national AI-based healthcare data ecosystem. The future of AI-enhanced healthcare necessitates a reimagining of healthcare education. Future professionals must be prepared to synergise with AI, requiring the development of AI-focused modules in medical and health curricula. By promoting stringent regulations, prioritising data privacy, and reimagining healthcare education, Indonesia can pave the way for a future where AI and human expertise harmoniously work together.

In conclusion, the integration of AI in healthcare presents a promising future for Indonesia. With careful consideration of potential challenges and the implementation of robust regulations, the country can leverage AI’s potential to improve healthcare accessibility and quality across the archipelago.

Reference url

Recent Posts

cemdisiran gMG treatment
Breakthrough in cemdisiran gMG treatment Advances Regulatory Landscape

By João L. Carapinha

June 25, 2026

Cemdisiran gMG treatment has cleared a critical hurdle after the FDA and EMA accepted Regeneron’s regulatory submissions for review in anti-AChR antibody-positive generalized myasthenia gravis (gMG). The investigational siRNA therapy targeting complement protein C5 could become the first subcutan...
Trodelvy ADC approval
Advancements in Breast Cancer Treatment Following Trodelvy ADC Approval

By João L. Carapinha

June 25, 2026

The Trodelvy ADC approval by the European Commission delivers the first antibody-drug conjugate approved for first-line use in adults with unresectable or metastatic triple-negative breast cancer who are ineligible for PD-1 or PD-L1 inhibitors. This
Cemiplimab Cervical Cancer Access
Cemiplimab Cervical Cancer Access Navigating Treatment and Value

By João L. Carapinha

June 24, 2026

Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...